Dow Jones Industrial Average

Dow Jones Industrial Average Articles

Intel, DowDuPont, UnitedHealth, and Procter & Gamble weighed on the DJIA index Wednesday.
There is a point that the yield on Treasury bonds will compete with stocks. That's still a ways higher, but some serious consideration needs to be given to what is happening.
Boeing, General Electric, Johnson & Johnson, and United Technologies were Tuesday's pacesetters among the Dow 30 stocks.
UnitedHealth, Disney, Pfizer, and General Electric were Monday's laggards among the DJIA stocks.
What a difference a week makes. From 2017's worst-performing DJIA stock to the top gainer in the first week of 2018. Can GE make the reversal last?
Intel was the worst performing Dow stock in the first week of 2018, entirely due to a recently revealed flaw that has been present in the company's chips for more than 20 years.
Boeing, Visa, UnitedHealth Group, and Caterpillar led the DJIA to a new all-time high Friday.
JPMorgan looks cheap compared to the markets in general, but with the run that it saw in 2017 and the outlook for 2018, this could be a steal. Or is it a value trap?
Nike is recognized across the globe as one of the premier names in sports apparel and shoes. While the company merits a premium for its stock, it shouldn’t scare investors away because there is...
Looking ahead to 2018, Disney may be facing some difficulties, but it stands to disrupt and continue to take market share.
Coca-Cola was one of the subpar Dow Jones Industrial Average components in 2017, and this coming year doesn’t look that much better for the stock.
The Dow is now full of technology stocks, and these components are going to have to do their part for the broad market to keep rallying in 2018.
GE, DowDuPont, Merck, and IBM lifted the DJIA to more than 25,000 on Thursday.
While 2017 found McDonald’s near the top of the food chain in terms of its performance within the Dow, up 45%, the restaurant chain will still be hungry in 2018.
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.